Relationship Graph Explorer

Follow the connections

Every herb, ingredient, formula, gene target, and disease — connected through real research. Search, pick a subject, and navigate the graph in any direction.

🌿

Herb

→

→

→

→

🧪

Evidence

23,295

trials · metas · refs

Plus 6,743 TCM formulas connecting herbs together

Subject Type: 🌿 Herbs ⚗️ Ingredients 📜 Formulas 🧬 Targets 🏥 Diseases

Quick picks: Taxol Oxytocin Morphine (?)-nicotine Testosterone Melatonin Caffeine L-ascorbic acid Progesterone Coumarins

⚗️ Ingredient

Etoposide

Open on HERB 2.0 ↗

Clinical Trials

Meta-Analyses

PubMed References

Top Conditions Studied with Etoposide

SCLC 1 Advanced Neuroendocrine Carcinoma 1 Neuroendocrine Neoplasms 1 Adrenocortical Carcinoma 1 Neuroendocrine Carcinoma of the Bladder|Bladder Cancer 1 Multiple Myeloma 1 The Cochrane Gynaecological, Neuro-oncology and Orphan Cance 1 Mammary Neoplasms, Human 1 Small-cell lung cancer (SCLC), which is characterized by sho 1 Lymphoma|Multiple Myeloma 1 Palliative treatment of children with solid tumours. 1 Hemophagocytic Lymphohistiocytosis 1

📋 Sample Trials

NCT05510089

Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies

Recruiting

NCT05536154

Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies

Recruiting

NCT05546060

Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH

Recruiting · Phase 1

📊 Sample Meta-Analyses

CRD42019126641

Use of oral etoposide as palliation in paediatric oncology - experience of a single institution and systematic review

Palliative treatment of children with solid tumours.

CRD42020197226

Immune checkpoint inhibitors combined with etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: a bayesian network meta-analysis of randomized controlled trials

Small-cell lung cancer (SCLC), which is characterized by short doubling time, ex

CRD42020176454

Oral etoposide for treatment and/or maintenance treatment of recurrent epithelial ovarian cancer [Cochrane protocol]

The Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group

📚 Sample References

None linked yet.

⚗️ All Ingredient data fields for Etoposide

⚗️ Identity

Name

Etoposide

Aliases / Synonyms

VePesid; 33419-42-0; Toposar; trans-Etoposide; (-)-Etoposide; Lastet; Zuyeyidal; Etoposidum; Etoposido

🧪 Chemistry

Molecular Weight

588.5620

LogP

1.3386

Drug-likeness

0.43

H-Bond Acceptors

H-Bond Donors

Rotatable Bonds

🔬 Structures

Canonical SMILES

CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O

Isomeric SMILES

C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O

InChIKey

VJJPUSNTGOMMGY-MRVIYFEKSA-N

InChI

InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1

🔗 External References

HERB DB

HBIN026006 ↗

PubChem CID

36462 ↗

NPASS

NPC185498

TCM-ID

12870

🔍 Raw view — every non-empty column on this row (28 fields)

name

Etoposide

common names

VePesid; 33419-42-0; Toposar; trans-Etoposide; (-)-Etoposide; Lastet; Zuyeyidal; Etoposidum; Etoposido

herb ingredient id

HBIN026006

canonical smiles

CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O

isomeric smiles

C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O

inchi

inchikey

VJJPUSNTGOMMGY-MRVIYFEKSA-N

mol wt

588.5620

num h acceptors

num h donors

mol logp

1.3386

num rotatable bonds

drug likeness

0.43

tcm id ingredient id

12870

pubchem cid

36462

npass id

NPC185498

🏥 Linked Health Topics

4 · studied for these conditions (text bridge)

Multiple Myeloma

disease

Adrenocortical Carcinoma

disease

Small Cell Lung Cancer Recurrent

disease

Mammary Neoplasms, Human

disease

📋 Clinical Trials

12 · subject of clinical study

NCT05510089 Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Pat

→ Hematological Malignancy

NCT05536154 Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoi

→ Lymphoma|Multiple Myeloma

NCT05546060 Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in H

→ Hemophagocytic Lymphohistiocytosis

NCT05312671 Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

→ Small Cell Neuroendocrine Carcinoma of Bladder|Bla

NCT05361395 First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhi

→ Extensive Stage Small Cell Lung Cancer

NCT05517213 High-dose Chemotherapy+G-CSF in Peripheral Blood Stem Cell Mobilization in Patie

→ Multiple Myeloma

NCT05309629 Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy

→ Extensive-stage Small-cell Lung Cancer

NCT05595460 Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

→ SCLC,Extensive Stage

NCT05224141 Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemot

→ Small Cell Lung Carcinoma

NCT05762419 FUS Etoposide for DMG

→ Diffuse Intrinsic Pontine Glioma|Diffuse Midline G

NCT05781633 The Efficacy and Safety of Eutideron, Etoposide, and Bevacizumab in Patients Wit

→ Mammary Neoplasms, Human

NCT06091124 Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder C

→ Neuroendocrine Carcinoma of the Bladder|Bladder Ca

📊 Meta-Analyses

3 · systematic review

CRD42019126641 Use of oral etoposide as palliation in paediatric oncology - experience of a sin

→ Palliative treatment of children with solid tumour

CRD42020197226 Immune checkpoint inhibitors combined with etoposide and platinum as first-line

→ Small-cell lung cancer (SCLC), which is characteri

CRD42020176454 Oral etoposide for treatment and/or maintenance treatment of recurrent epithelia

→ The Cochrane Gynaecological, Neuro-oncology and Or

How relationships are computed

Clinical Trials / Meta-Analyses / References: direct foreign-key link via subject_entity_id (Phase 2d wireup)
Formula ↔ Herbs: text bridge via formulas.herbs_in_pinyin matching herbs.pinyin_name
Herb ↔ Ingredient: empty — needs HERB_herb_ingredient import
Ingredient ↔ Target: empty — needs HERB_ingredient_target import
Target ↔ Disease: empty — needs HERB_target_disease import
Herb → Target → Disease (full chemical spine): awaiting Phase 2e link tables